AI
AKBA icon

Axiom Investors’s Akebia Therapeutics AKBA Stock Holding History

Axiom Investors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-30,600
Closed -$677K – 156
2014
Q3 		$677K Buy
+30,600
New +$703K 0.02% 145

Other funds holding AKBA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Axiom Investors's AKBA Position: Q4 2014 in Review

Axiom Investors sold out of Akebia Therapeutics (AKBA) in Q4 2014, closing a stake of 30,600 shares — an estimated $677K sold.

Axiom Investors first reported a position in AKBA in Q3 2014 and held it in 1 quarter. The position peaked at $677K in Q3 2014. 57 funds tracked by Wall St. Rank hold AKBA as of Q4 2014.

  • Axiom Investors reported no remaining Akebia Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Axiom Investors sold 30,600 Akebia Therapeutics shares in Q4 2014, an estimated $677K.
  • Axiom Investors first reported a position in Akebia Therapeutics in Q3 2014 and held it in 1 quarter.
  • Axiom Investors's Akebia Therapeutics position peaked at $677K in Q3 2014.
  • 57 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2014.

Based on Axiom Investors's 13F filing for Q4 2014, filed 12 Feb 2015.